

# Nuggehally R Srinivas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5156714/publications.pdf>

Version: 2024-02-01

251  
papers

3,594  
citations

136740

32  
h-index

205818

48  
g-index

252  
all docs

252  
docs citations

252  
times ranked

3694  
citing authors

#	ARTICLE	IF	CITATIONS
1	A concise review of bioanalytical methods of small molecule immuno-oncology drugs in cancer therapy. <i>Biomedical Chromatography</i> , 2021, 35, e4996.	0.8	3
2	Whole blood or plasma: what is the ideal matrix for pharmacokinetic-driven drug candidate selection?. <i>Future Medicinal Chemistry</i> , 2021, 13, 157-171.	1.1	13
3	Enantioselective in vitro ADME, absolute oral bioavailability, and pharmacokinetics of (S)-lumefantrine and (+)-lumefantrine in mice. <i>Xenobiotica</i> , 2021, 51, 202-209.	0.5	1
4	Pharmacokinetics of Darolutamide in Mouse - Assessment of the Disposition of the Diastereomers, Key Active Metabolite and Interconversion Phenomenon: Implications to Cancer Patients. <i>Drug Metabolism Letters</i> , 2021, 14, 54-65.	0.5	4
5	Pronounced influence of presystemic metabolism on the metabolic disposition of imrecoxib in renally impaired patients. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 469-471.	0.8	2
6	Relevance of preclinical rodent pharmacokinetics in the selection of a companion antibiotic for combining with beta-lactamase inhibitor. <i>Xenobiotica</i> , 2020, 50, 815-821.	0.5	0
7	A review of bioanalytical methods for chronic lymphocytic leukemia drugs and metabolites in biological matrices. <i>Biomedical Chromatography</i> , 2020, 34, e4742.	0.8	1
8	ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00565.	1.1	11
9	Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment. <i>Drug Safety</i> , 2020, 43, 711-725.	1.4	37
10	Protein Binding and Stability of Drug Candidates: The Achilles Heel in In Vitro Potency Assays. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020, 45, 427-432.	0.6	1
11	Novel methodology to perform incurred sample reanalysis on dried blood spot cards: Experimental data using darolutamide and filgotinib. <i>Biomedical Chromatography</i> , 2020, 34, e4938.	0.8	2
12	Simultaneous determination of colchicine and febuxostat in rat plasma: Application in a rat pharmacokinetic study. <i>Biomedical Chromatography</i> , 2020, 34, e4939.	0.8	9
13	Incurred sample reanalysis of cefuroxime in rabbit ocular tissues - A case study. <i>Biomedical Chromatography</i> , 2020, 34, e4737.	0.8	4
14	Impact of collagen-induced arthritis on the pharmacokinetic disposition of voriconazole, a widely used antifungal agent: in vitro and in vivo investigations in DBA/1J mice. <i>Xenobiotica</i> , 2019, 49, 698-707.	0.5	0
15	Prediction of Human Pharmacokinetics of Bendamustine from Preclinical Species Pharmacokinetics Based on Normalizing Time Course Profiles. <i>Drug Research</i> , 2019, 69, 32-39.	0.7	2
16	Combination of flavonoids with azole drugs for fungal infections: key pharmacokinetic challenges. <i>Future Microbiology</i> , 2019, 14, 733-738.	1.0	3
17	A sensitive quantitative assay for the determination of propafenone and two metabolites, 5-hydroxypropafenone and N-depropylpropafenone, in human K2EDTA plasma using LC-MS/MS with ESI operated in positive mode. <i>Biomedical Chromatography</i> , 2019, 33, e4671.	0.8	0
18	Pharmacokinetic evaluation of differential drug release formulations of rabeprazole in dogs. <i>Drug Development and Industrial Pharmacy</i> , 2019, 45, 1459-1467.	0.9	3

#	ARTICLE	IF	CITATIONS
19	Prediction of Human Pharmacokinetics of Fomepizole from Preclinical Species Pharmacokinetics Based on Normalizing Time Course Profiles. <i>AAPS PharmSciTech</i> , 2019, 20, 221.	1.5	1
20	Comment on: Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Healthy Chinese Subjects. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019, 44, 719-721.	0.6	1
21	Simultaneous determination of bendamustine and $^3\text{H}$ -hydroxybendamustine in mice dried blood spots and its application in a mice pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 174, 168-174.	1.4	6
22	Use of Cocktail Probe Drugs for Indexing Cytochrome P450 Enzymes in Clinical Pharmacology Studies – Review of Case Studies. <i>Drug Metabolism Letters</i> , 2019, 13, 3-18.	0.5	13
23	Differential pharmacokinetic drug-drug interaction potential of eletriptan between oral and subcutaneous routes. <i>Xenobiotica</i> , 2019, 49, 1202-1208.	0.5	1
24	Incurred sample reanalysis in drug discovery bioanalysis. <i>Biomedical Chromatography</i> , 2019, 33, e4430.	0.8	10
25	Comment on: Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study. <i>Clinical Drug Investigation</i> , 2019, 39, 105-107.	1.1	1
26	Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 130, 107-113.	1.9	6
27	Assessment of the in vitro cytochrome P450 (CYP) inhibition potential of ZYTP1, a novel poly (ADP-ribose) polymerase inhibitor. <i>Xenobiotica</i> , 2019, 49, 1164-1172.	0.5	2
28	Review of DBS methods as a quantitative tool for anticancer drugs. <i>Biomedical Chromatography</i> , 2019, 33, e4445.	0.8	19
29	Rats and rabbits as pharmacokinetic screening tools for long acting intramuscular depots: case study with paliperidone palmitate suspension. <i>Xenobiotica</i> , 2019, 49, 415-421.	0.5	5
30	Strategy for the Prediction of Steady-State Exposure of Digoxin to Determine Drug-Drug Interaction Potential of Digoxin With Other Drugs in Digitalization Therapy. <i>American Journal of Therapeutics</i> , 2019, 26, e54-e65.	0.5	1
31	Lack of Translatable Proinflammatory Cytokines in Cerebrospinal Fluid in Rats With Increased Hyperalgesia With or Without Fentanyl Treatment. <i>Anesthesia and Analgesia</i> , 2018, 126, 2150.	1.1	1
32	Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2018, 43, 373-382.	0.6	8
33	Letter: high oral dose of taurine for portal hypertension in cirrhotic patients – some clinical pharmacology considerations. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 861-862.	1.9	0
34	Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1385-1398.	1.6	51
35	Reduced Ketobemidone Usage in Quadratus Lumborum Block Patients After Cesarean Delivery: Clinical Pharmacology Views. <i>Anesthesia and Analgesia</i> , 2018, 127, 311-311.	1.1	3
36	Antiretroviral Therapy With Efavirenz in HIV-1 Infected Pregnant Women: Understanding the Possible Mechanisms for Drug-Drug Interaction. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 570-570.	2.3	1

#	ARTICLE	IF	CITATIONS
37	Limited Sampling Strategy for Accurate Prediction of Pharmacokinetics of Saroglitazar: A 3-point Linear Regression Model Development and Successful Prediction of Human Exposure. <i>Clinical Therapeutics</i> , 2018, 40, 456-468.e1.	1.1	2
38	Influence of Morbid Obesity on the Clinical Pharmacokinetics of Various Anti-Infective Drugs: Reappraisal Using Recent Case Studies—Issues, Dosing Implications, and Considerations. <i>American Journal of Therapeutics</i> , 2018, 25, e224-e246.	0.5	10
39	Reappraisal and perspectives of clinical drug–drug interaction potential of $\alpha$ -glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus. <i>Xenobiotica</i> , 2018, 48, 89-108.	0.5	49
40	Influence of acute and chronic kidney failure in rats on the disposition and pharmacokinetics of ZYAN1, a novel prolyl hydroxylase inhibitor, for the treatment of chronic kidney disease-induced anemia. <i>Xenobiotica</i> , 2018, 48, 37-44.	0.5	10
41	Ponesimod, a selective sphingosine 1-phosphate (S1P <sub>1</sub> ) receptor modulator for autoimmune diseases: review of clinical pharmacokinetics and drug disposition. <i>Xenobiotica</i> , 2018, 48, 442-451.	0.5	14
42	Consequences of daily corticosteroid dosing with or without pre-treatment with quinidine on the in vivo cytochrome P450 2D (CYP2D) enzyme in rats: effect on O-demethylation activity of dextromethorphan and expression levels of CYP2D1 mRNA. <i>Xenobiotica</i> , 2018, 48, 1-10.	0.5	7
43	Area under the curve predictions of dalbavancin, a new lipoglycopeptide agent, using the end of intravenous infusion concentration data point by regression analyses such as linear, log-linear and power models. <i>Xenobiotica</i> , 2018, 48, 148-156.	0.5	3
44	Stereoselective and nonstereoselective pharmacokinetics of rabeprazole—an overview. <i>Xenobiotica</i> , 2018, 48, 422-432.	0.5	8
45	Review of HPLC and LC–MS/MS assays for the determination of various nonsteroidal antiandrogens used in the treatment of prostate cancer. <i>Biomedical Chromatography</i> , 2018, 32, e4034.	0.8	9
46	Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers. <i>Clinical Pharmacokinetics</i> , 2018, 57, 87-102.	1.6	29
47	Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPAR $\alpha$ / $\beta$ Agonist, in Healthy Adult Subjects. <i>Clinical Drug Investigation</i> , 2018, 38, 57-65.	1.1	11
48	A review of bioanalytical quantitative methods for selected sphingosine 1-phosphate receptor modulators. <i>Biomedical Chromatography</i> , 2018, 32, e4109.	0.8	4
49	Chirality and neuropsychiatric drugs: an update on stereoselective disposition and clinical pharmacokinetics of bupropion. <i>Xenobiotica</i> , 2018, 48, 945-957.	0.5	12
50	Arenobufagin: A potential novel opportunity for prostate cancer treatment—Intriguing mechanistic data but some questions on in vivo translatability. <i>Pharmacological Research</i> , 2018, 128, 400-401.	3.1	1
51	Preclinical evaluation of saroglitazar magnesium, a dual PPAR- $\alpha$ / $\beta$ agonist for treatment of dyslipidemia and metabolic disorders. <i>Xenobiotica</i> , 2018, 48, 1268-1277.	0.5	7
52	LC–ESI–MS/MS determination of 4-methylpyrazole in dog plasma and its application to a pharmacokinetic study in dogs. <i>Biomedical Chromatography</i> , 2018, 32, e4065.	0.8	1
53	Key Pharmacokinetic Essentials of Fixed-Dosed Combination Products: Case Studies and Perspectives. <i>Clinical Pharmacokinetics</i> , 2018, 57, 419-426.	1.6	9
54	Extrapolation of pharmacokinetic interaction data of proton pump inhibitors obtained in healthy subjects for oral targeted therapies in cancer patients. <i>International Journal of Pharmacokinetics</i> , 2018, 3, 93-97.	0.5	0

#	ARTICLE	IF	CITATIONS
55	In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole, Aldicarb, Methiocarb, Montelukast and Ziprasidone. <i>Drug Metabolism Letters</i> , 2018, 12, 101-116.	0.5	6
56	Regression modeling strategy for prediction of AUC of evogliptin, a novel dipeptidyl peptidase IV inhibitor in humans, using single dose PK data. <i>International Journal of Pharmacokinetics</i> , 2018, 3, 23-38.	0.5	0
57	Opposite effects of acute kidney injury on pharmacokinetics of renally and hepatobiliary excreted drugs. <i>International Journal of Pharmacokinetics</i> , 2018, 3, 81-90.	0.5	0
58	Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives. <i>Xenobiotica</i> , 2017, 47, 354-368.	0.5	27
59	Differences in the Prediction of Area Under the Curve for a Protease Inhibitor Using Trough Versus Peak Concentration: Assessment Using Published Pharmacokinetic Data for Indinavir. <i>American Journal of Therapeutics</i> , 2017, 24, e405-e418.	0.5	5
60	Stereoselective Conversion of Ketoprofen in Men Versus Women from Two Different Oral Dosage Formulations: Observations and Introspection of the Pharmacokinetic Data. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 165-166.	0.6	1
61	Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic. <i>Infectious Diseases</i> , 2017, 49, 483-492.	1.4	24
62	A sensitive quantitative assay for the determination of propafenone and two metabolites, 5-hydroxypropafenone and <i>o</i> -depropylpropafenone, in human K <sub>2</sub> EDTA plasma using LC-MS/MS with ESI operated in positive mode. <i>Biomedical Chromatography</i> , 2017, 31, e3967.	0.8	6
63	Preclinical pharmacokinetics of novel trioxane antimalarial drug (99/411) – several unanswered questions and development perspectives. <i>Biomedical Chromatography</i> , 2017, 31, e3938.	0.8	0
64	One should avoid retro-orbital pharmacokinetic sample collections for intranasal dosing in rats: Illustration of spurious pharmacokinetics generated for anti-migraine drugs zolmitriptan and eletriptan. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 106, 87-93.	1.9	0
65	Improved oral bioavailability and brain accumulation of afatinib due to dual inhibition of the efflux mechanisms of BCRP and Pgp transporters – What next?. <i>Pharmacological Research</i> , 2017, 123, 143.	3.1	1
66	Severe metabolic impairment with increasing age for CYP3A and CYP2D substrates in rats: Possible consequences for drug development. <i>Biomedical Chromatography</i> , 2017, 31, e4009.	0.8	0
67	Pharmacodynamics of Insulin Preparations Administered in Different Subcutaneous Injection Sites: Are There Differences Between Healthy Subjects Versus Diabetic Patients?. <i>Clinical Drug Investigation</i> , 2017, 37, 881-884.	1.1	1
68	Letter: sublingual dosing of tacrolimus in transplant patients – interesting concept to overcome first pass effects. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 79-80.	1.9	2
69	Sensitive and specific LC-ESI-MS/MS method for determination of ZYDPLA1, a novel long-acting dipeptidyl peptidase 4 inhibitor in rat plasma: An application for toxicokinetic study in rats. <i>Biomedical Chromatography</i> , 2017, 31, e3984.	0.8	2
70	Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 915-933.	0.6	59
71	Comments on: <i>In Vitro</i> and <i>In Vivo</i> pharmacokinetics and toxicity evaluation of curcumin incorporated titanium dioxide nanoparticles for biomedical applications. <i>Chemico-Biological Interactions</i> , 2017, 277, 145.	1.7	1
72	Letter: CYP2C19 polymorphisms and exacerbation of rabeprazole's effects on celecoxib-induced small bowel injury. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 706-707.	1.9	1

#	ARTICLE	IF	CITATIONS
73	Comments on: "Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension". <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 1019-1021.	0.6	1
74	Letter: clinical response to pioglitazone in nonalcoholic steatohepatitis [ <i>sc</i> >NASH</sc>] treatment" use of pharmacokinetic surrogate. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 470-471.	1.9	1
75	Intravenous-to-oral switch in antimicrobial therapy: clinical pharmacology considerations and perspectives. <i>Future Microbiology</i> , 2017, 12, 847-851.	1.0	4
76	Comment on: "A Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Orally Administered Des-aspartate Angiotensin I in Healthy Subjects". <i>Drugs in R and D</i> , 2017, 17, 241-242.	1.1	1
77	Comment on: "Modeling the Relationship between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer". <i>Clinical Pharmacokinetics</i> , 2017, 56, 211-212.	1.6	1
78	Evaluation of In Vitro Cytochrome P450 Inhibition and In Vitro Fate of Structurally Diverse N-Oxide Metabolites: Case Studies with Clozapine, Levofloxacin, Roflumilast, Voriconazole and Zopiclone. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 677-688.	0.6	19
79	Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine. <i>Biomedical Chromatography</i> , 2017, 31, e3807.	0.8	32
80	Interspecies scaling of urinary excretory amounts of nine drugs belonging to different therapeutic areas with diverse chemical structures " accurate prediction of the human urinary excretory amounts. <i>Xenobiotica</i> , 2017, 47, 112-118.	0.5	3
81	An LC-MS/MS assay for the quantitative determination of 2-pyridyl acetic acid, a major metabolite and key surrogate for betahistine, using low-volume human K <sub>2</sub> EDTA plasma. <i>Biomedical Chromatography</i> , 2017, 31, e3790.	0.8	1
82	Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview. <i>Xenobiotica</i> , 2017, 47, 1015-1026.	0.5	18
83	Review of the bioanalytical methods for the determination of methotrexate and its metabolites in <i>in vitro</i> , preclinical and clinical studies: Case studies and perspectives. <i>Biomedical Chromatography</i> , 2017, 31, e3849.	0.8	7
84	Review of Pharmacokinetic Data of Different Drug Classes in Goto-Kakizaki Rats, a Non-obese Model for Type 2 Diabetes Mellitus: Case Studies and Perspectives. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 173-182.	0.6	4
85	Human biliary amount prediction using simple, bile flow-rate corrected and uridine diphosphate glucuronosyltransferase activity corrected allometric methods. <i>International Journal of Pharmacokinetics</i> , 2017, 2, 173-182.	0.5	0
86	Clinical drug-drug interactions of bosentan, a potent endothelial receptor antagonist, with various drugs: Physiological role of enzymes and transporters. <i>General Physiology and Biophysics</i> , 2016, 35, 243-258.	0.4	18
87	A comprehensive review of the published assays for the quantitation of the immunosuppressant drug mycophenolic acid and its glucuronidated metabolites in biological fluids. <i>Biomedical Chromatography</i> , 2016, 30, 721-748.	0.8	15
88	Understanding the role of tariquidar, a potent Pgp inhibitor, in combination trials with cytotoxic drugs: What is missing?. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1097-1098.	1.1	14
89	Enantioselective Pharmacokinetics of Bambuterol in Preclinical Species: Does S-bambuterol Influence the Clearance of the R-antipode?. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2016, 41, 197-198.	0.6	0
90	Clinical Drug "Drug Pharmacokinetic Interaction Potential of Sucralfate with Other Drugs: Review and Perspectives. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2016, 41, 469-503.	0.6	9

#	ARTICLE	IF	CITATIONS
91	Prediction of micafungin area under the curve data by using peak concentration: applicability and utility in antifungal therapy. <i>Future Microbiology</i> , 2016, 11, 485-490.	1.0	1
92	Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease – should one consider disease location?. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 771-772.	1.9	2
93	Verapamil and pristimerin pharmacokinetic drug-drug interaction study in rats – perspectives. <i>Biomedical Chromatography</i> , 2016, 30, 2074-2074.	0.8	0
94	Availability of plethora of bioanalytical assays for several commonly prescribed drugs – a problem of plenty: perspectives. <i>Biomedical Chromatography</i> , 2016, 30, 668-669.	0.8	0
95	Prostaglandin E1 therapy with alprostadil and risk reduction in early hepatic cellular carcinoma after liver transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 172-173.	1.9	3
96	Letter: vonoprazan, a long-lasting acid suppressor of the gastric H+, K+-ATPases with - implications for renal H+, K+-ATPases. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 442-443.	1.9	2
97	Letter: ileal bile acid transporter inhibition - is there a potential for drug-drug interaction?. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 750-751.	1.9	1
98	Letter: faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1239-1240.	1.9	1
99	Letter: probing the consequences of potent acid inhibition by vonoprazan. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 304-305.	1.9	1
100	Is There Saturation in the Conversion of Baicalein to Baicalin After Oral Chewable Tablets: Retrospective Evaluation of the Human Pharmacokinetic Data?. <i>Clinical Drug Investigation</i> , 2016, 36, 1075-1076.	1.1	2
101	Transdermal Rivastigmine Delivery for Alzheimer Disease: Amenability of Exposure Predictions of Rivastigmine and Metabolite, NAP226-90, by Linear Regression Model Using Limited Samples. <i>Clinical Neuropharmacology</i> , 2016, 39, 169-177.	0.2	3
102	Is the inhibition of the liver uptake and biliary excretion, via transporters, the likely mechanism for the increased exposure of vitexin-rhamnoside with bile salts in rats?. <i>Biomedical Chromatography</i> , 2016, 30, 1701-1702.	0.8	0
103	Pharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple Mechanisms. <i>Drugs in R and D</i> , 2016, 16, 141-148.	1.1	28
104	Applicability of a Single Time Point Strategy for the Prediction of Area Under the Concentration Curve of Linezolid in Patients: Superiority of C trough- over C max-Derived Linear Regression Models. <i>Drugs in R and D</i> , 2016, 16, 69-79.	1.1	15
105	A concise review of the bioanalytical methods for the quantitation of sitagliptin, an important dipeptidyl peptidase-4 (DPP4) inhibitor, utilized for the characterization of the drug. <i>Biomedical Chromatography</i> , 2016, 30, 749-771.	0.8	13
106	Quantitative determination of saroglitazar, a predominantly PPAR alpha agonist, in human plasma by a LC-MS/MS method utilizing electrospray ionization in a positive mode. <i>Biomedical Chromatography</i> , 2016, 30, 1900-1907.	0.8	3
107	Is there a differential conversion of artesunate to dihydroartemisinin in pregnant postpartum patients with malaria after oral artesunate dosing?. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 389-390.	1.1	4
108	Should commonly prescribed drugs be avoided as internal standard choices in new assays for clinical samples?. <i>Bioanalysis</i> , 2016, 8, 607-610.	0.6	17

#	ARTICLE	IF	CITATIONS
109	Intranasal Pharmacokinetic Data for Triptans Such as Sumatriptan and Zolmitriptan Can Render Area Under the Curve (AUC) Predictions for the Oral Route: Strategy Development and Application. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2016, 30, 13-24.	0.5	2
110	Prediction of area under the concentration-time curve for lopinavir from peak or trough lopinavir concentrations in patients receiving lopinavir-ritonavir therapy. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 376-385.	0.5	2
111	Relationship Between Buprenorphine Dosing and Triglyceride Lowering and Creatinine Kinase Elevation in Felines: Possible Human Implications. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2016, 30, 49-52.	0.5	1
112	Interspecies scaling of excretory amounts using allometry - retrospective analysis with rifapentine, aztreonam, carumonam, pefloxacin, miloxacin, trovafloxacin, doripenem, imipenem, ceftazidime, linezolid for urinary excretion and rifapentine, cabotegravir, and dolutegravir for fecal excretion. <i>Xenobiotica</i> , 2016, 46, 784-792.	0.5	4
113	The Interesting Case of Acyclovir Delivered Using Chitosan in Humans: Is it a Drug Issue or Formulation Issue?. <i>Pharmaceutical Research</i> , 2016, 33, 543-547.	1.7	3
114	The pharmacokinetic disposition of delta-9-tetrahydrocannabinol and its metabolite in elderly patients with dementia - role of differential presystemic conversion?. <i>Psychopharmacology</i> , 2016, 233, 157-158.	1.5	1
115	Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites. <i>Drug Development and Industrial Pharmacy</i> , 2016, 42, 945-957.	0.9	11
116	Limited Sampling Strategy for the Prediction of Area Under the Curve (AUC) of Statins: Reliability of a Single Time Point for AUC Prediction for Pravastatin and Simvastatin. <i>Drug Research</i> , 2016, 66, 82-93.	0.7	7
117	Gastric emptying and acetaminophen: lessons learnt from the several co-administered drugs on the experimental design. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 369-371.	0.8	0
118	Commonality of rituximab pharmacokinetic disposition in nephrotic syndrome and autoimmune cytopenias in chronic lymphocytic leukemia patients. <i>Pediatric Nephrology</i> , 2016, 31, 335-336.	0.9	2
119	Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide: Should Consideration Be Given to Canalicular Efflux Transporters?. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 563-563.	1.3	2
120	Letter: gluten digestion in the stomach and duodenum by <i>Aspergillus niger</i> -derived enzyme - things to ponder. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 946-946.	1.9	1
121	Comment on: "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modelling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection". <i>Clinical Pharmacokinetics</i> , 2015, 54, 1293-1295.	1.6	2
122	First-in-man study of ACT453859, a potent CRTH2 antagonist - Is the metabolite formation influenced by a polymorphic enzyme?. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1432-1432.	1.0	1
123	Linagliptin - Role in the Reversal of ACE-Mediated Impairment of Insulin Signaling and Reduced Neurotoxicity in AD Pathogenesis: Some Considerations. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 962-963.	1.9	6
124	Therapeutic drug monitoring of cyclosporine and area under the curve prediction using a single time point strategy: appraisal using peak concentration data. <i>Biopharmaceutics and Drug Disposition</i> , 2015, 36, 575-586.	1.1	16
125	Oral tramadol pharmacokinetics in pediatric subjects versus adults - Is there a role of delayed gastric emptying in pediatric subjects?. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 473-474.	0.8	1
126	Recent trends in preclinical drug-drug interaction studies of flavonoids - Review of case studies, issues and perspectives. <i>Phytotherapy Research</i> , 2015, 29, 1679-1691.	2.8	43



#	ARTICLE	IF	CITATIONS
127	Retrospective and Prospective Human Intravenous and Oral Pharmacokinetic Projection of Dipeptidyl peptidase-IV Inhibitors Using Simple Allometric Principles – Case Studies of ABT-279, ABT-341, Alogliptin, Carmegliptin, Sitagliptin and Vildagliptin. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2015, 18, 434.	0.9	5
128	Letter: infliximab therapy for patients with inflammatory bowel disease – some unanswered questions. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1133-1133.	1.9	1
129	Schedule-dependent modulation of the pharmacokinetics of MK-2206, an oral pan-AKT inhibitor: perspectives. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1315-1316.	1.1	0
130	Fidaxomicin Pharmacokinetics in Humans: Is There a Role of Biliary Excretion?. <i>Clinical Drug Investigation</i> , 2015, 35, 531-532.	1.1	0
131	Biochanin A: Understanding the Complexities in the Paradoxical Drug–Drug Interaction Potential. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2015, 40, 119-125.	0.6	15
132	Comment on: –Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag–. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 371-372.	1.0	1
133	Phenylephrine Pharmacokinetics and First-Pass Metabolism: What Is an Ideal Pharmacokinetic Surrogate?. <i>Clinical Drug Investigation</i> , 2015, 35, 851-853.	1.1	0
134	Acetaminophen Absorption Kinetics in Altered Gastric Emptying: Establishing a Relevant Pharmacokinetic Surrogate Using Published Data. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2015, 29, 115-119.	0.5	12
135	Bioanalysis in oncology drug discovery. <i>Biomarkers in Medicine</i> , 2015, 9, 877-886.	0.6	6
136	Differential Consequences of Tramadol in Overdosing: Dilemma of a Polymorphic Cytochrome P450 2D6–Mediated Substrate. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2015, 29, 272-275.	0.5	3
137	Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors – review of assay methodologies and perspectives. <i>Biomedical Chromatography</i> , 2015, 29, 803-834.	0.8	34
138	Strategies for preclinical pharmacokinetic investigation in streptozotocin-induced diabetes mellitus (DMIS) and alloxan-induced diabetes mellitus (DMIA) rat models: case studies and perspectives. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2015, 40, 1-12.	0.6	9
139	Dilemma with Matrix Effect in Bioanalysis – Perspectives from Bioavailability/Bioequivalence Studies for Product Registration?. <i>Drug Research</i> , 2014, 64, 335-336.	0.7	4
140	Transdermal buprenorphine–interesting observations on the metabolite norbuprenorphine levels in elderly subjects. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1607-1608.	0.8	0
141	New lumefantrine self nanoemulsifying delivery system – will it by-pass lymphatic transport mechanisms?. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2013, 21, 55.	0.9	0
142	Commentary on: –study of the pharmacokinetic changes of tramadol in diabetic rats–is the handicapped renal pathway in DMIS contributing for the increased bioavailability of tramadol?. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2013, 21, 23.	0.9	1
143	The re–emergence of salting–out association with acetonitrile for modern day bioanalysis. <i>Biomedical Chromatography</i> , 2013, 27, 545-547.	0.8	4
144	Is pomegranate juice a potential perpetrator of clinical drug–drug interactions? Review of the in vitro, preclinical and clinical evidence. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2013, 38, 223-229.	0.6	29

#	ARTICLE	IF	CITATIONS
145	Phase I and beyond – the importance of switching to patient’s plasma: considerations and perspectives on bioanalytical procedures. <i>Bioanalysis</i> , 2013, 5, 2215-2218.	0.6	0
146	Review of the quantitative analysis of cholesteryl ester transfer protein inhibitors. <i>Biomedical Chromatography</i> , 2013, 27, 1259-1272.	0.8	2
147	Do We Have Clarity on the Therapeutic Levels of Morphine and Its Metabolites: Seeking Answers for the Dilemma?. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2013, 27, 163-166.	0.5	2
148	Cranberry Juice Ingestion and Clinical Drug-Drug Interaction Potentials; Review of Case Studies and Perspectives. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2013, 16, 289.	0.9	42
149	The Observed Correlation between in vivo Clinical Pharmacokinetic Parameters and in vitro Potency of VEGFR-2 Inhibitors. <i>Arzneimittelforschung</i> , 2012, 62, 194-201.	0.5	12
150	A strategy for extending the applicability of a validated plasma calibration curve to quantitative measurements in multiple tissue homogenate samples: a case study from a rat tissue distribution study of JI-101, a triple kinase inhibitor. <i>Biomedical Chromatography</i> , 2012, 26, 419-424.	0.8	2
151	Review of HPLC methods and HPLC methods with mass spectrometric detection for direct determination of aspirin with its metabolite(s) in various biological matrices. <i>Biomedical Chromatography</i> , 2012, 26, 906-941.	0.8	20
152	Highly sensitive method for the determination of JI-101, a multi-kinase inhibitor in human plasma and urine by LC-MS/MS-ESI: method validation and application to a clinical pharmacokinetic study. <i>Biomedical Chromatography</i> , 2012, 26, 232-238.	0.8	2
153	Pharmacokinetics of Tolbutamide in Acute Renal Failure Induced by Glycerol: Speculative Thoughts and Perspectives. <i>Drug Metabolism and Pharmacokinetics</i> , 2011, 26, 216-217.	1.1	4
154	PK/PD modeling of rabeprazole in CYP2C19 genotypes: consideration of the influence of thio-ether metabolite, CYP3A4, accumulation and CYP2D6 polymorphism may help to better develop and validate the model. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 965-966.	0.8	1
155	Intravenous prediction of human pharmacokinetic parameters for ketorolac, a non-steroidal anti-inflammatory agent, using allometry approach. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2011, 36, 87-93.	0.6	3
156	The rationality for using prodrug approach in drug discovery programs for new xenobiotics: opportunities and challenges. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2011, 36, 49-59.	0.6	10
157	Highly sensitive method for the determination of a novel triple kinase inhibitor with anti-cancer activity, JI-101, in rat plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study. <i>Biomedical Chromatography</i> , 2011, 25, 794-800.	0.8	2
158	An overview of various validated HPLC and LC-MS/MS methods for quantitation of drugs in bile: challenges and considerations. <i>Biomedical Chromatography</i> , 2011, 25, 65-81.	0.8	13
159	Incurred sample reanalysis: dilemma in its applicability – should it be practiced for all bioanalytical assays involving single (parent or metabolite) or multiple analytes (parent/metabolite or parent with) Tj ETQq1 1 0.784314 rgBT /Over	0.8	10
160	Dealing with matrix effect: should there be a cutoff limit for signal ion suppression in quantitative assay validation?. <i>Biomedical Chromatography</i> , 2011, 25, 740-742.	0.8	5
161	Sensitivity enhancement and matrix effect evaluation during summation of multiple transition pairs – case studies of clopidogrel and ramiprilat. <i>Biomedical Chromatography</i> , 2010, 24, 528-534.	0.8	14
162	Influence of number of calibration standards within a defined range on pharmacokinetic disposition – case studies with omeprazole and clopidogrel carboxylic acid. <i>Biomedical Chromatography</i> , 2010, 24, 544-549.	0.8	3

#	ARTICLE	IF	CITATIONS
163	Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypesâ€“focus on venlafaxine and O-desmethylenlafaxine. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 879-887.	0.8	19
164	Irinotecan and its active metabolite, SNâ€“38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. <i>Biomedical Chromatography</i> , 2010, 24, 104-123.	0.8	139
165	Altered disposition of drugs in acute renal failure rat models: drug development strategies and perspectives. <i>Arzneimittelforschung</i> , 2010, 60, 731-748.	0.5	8
166	Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives. <i>Xenobiotica</i> , 2010, 40, 357-367.	0.5	113
167	Antacid Use and Reduced Bioavailability of Oral Drugs. <i>Arzneimittelforschung</i> , 2009, 59, 327-334.	0.5	2
168	Torcetrapib for animal and human pharmacokinetic studies: applicability of chiral and achiral methodologies. <i>Bioanalysis</i> , 2009, 1, 619-628.	0.6	2
169	Considerations for Metabolite Pharmacokinetic Data in Bioavailability/Bioequivalence Assessments. <i>Arzneimittelforschung</i> , 2009, 59, 155-165.	0.5	6
170	Structurally Modified &#x2018;Dietary Flavonoids&#x2019;: Are these Viable Drug Candidates for Chemoprevention?. <i>Current Clinical Pharmacology</i> , 2009, 4, 67-70.	0.2	12
171	Prediction of Human Pharmacokinetic Parameters Using Animal Data and Principles of Allometry. <i>Arzneimittelforschung</i> , 2009, 59, 625-630.	0.5	3
172	Drugâ€“drug interaction studies in preclinical species: should metabolite(s) kinetics be studied?. <i>Xenobiotica</i> , 2009, 39, 193-196.	0.5	4
173	Unsuspected and Paradoxical Potential for Drug Interaction by Rifampin: Things to Ponder with Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2009, 199, 766-767.	1.9	7
174	Sensitivity enhancement in tandem liquid chromatographic mass spectrometric assays by summation of two transition ion pairs â€“ perspectives. <i>Journal of Separation Science</i> , 2009, 32, 483-486.	1.3	14
175	New thinking in the development of novel derivatization reagents for liquid chromatographyâ€“mass spectrometric detection. <i>Biomedical Chromatography</i> , 2009, 23, 107-108.	0.8	8
176	Measurement of xenobiotics in saliva: is saliva an attractive alternative matrix? Case studies and analytical perspectives. <i>Biomedical Chromatography</i> , 2009, 23, 3-25.	0.8	41
177	Clopidogrel: review of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drugâ€“drug interaction studies. <i>Biomedical Chromatography</i> , 2009, 23, 26-41.	0.8	46
178	Dodging matrix effects in liquid chromatography tandem mass spectrometric assaysâ€“ compilation of key learnings and perspectives. <i>Biomedical Chromatography</i> , 2009, 23, 451-454.	0.8	64
179	Enhancement of the impact of manuscript submissions toBMC: an editorial perspective. <i>Biomedical Chromatography</i> , 2009, 23, 1-2.	0.8	1
180	Bioanalytical methods for the determination of itraconazole and hydroxyitraconazole: overview from clinical pharmacology, pharmacokinetic, pharmacodynamic and metabolism perspectives. <i>Biomedical Chromatography</i> , 2009, 23, 677-691.	0.8	6

#	ARTICLE	IF	CITATIONS
181	Bioanalytical assay validation parameters re-visited: perspectives on stability studies. <i>Biomedical Chromatography</i> , 2009, 23, 1031-1033.	0.8	0
182	LC/MS/MS analysis of capsaicin using multiple transition pairs—some view points to ponder. <i>Biomedical Chromatography</i> , 2009, 23, 1129-1130.	0.8	3
183	Rationale for faster oral delivery to overcome the pathophysiology associated with dental pain — Biopharmaceutic and pharmacokinetic challenges. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2009, 34, 7-10.	0.6	1
184	Use of bile correction factors for allometric prediction of human pharmacokinetic parameters of torcetrapib, a facile cholesteryl ester transfer protein inhibitor. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2009, 34, 57-63.	0.6	5
185	Tigecycline and cyclosporine interaction—an interesting case of biliary-excreted drug enhancing the oral bioavailability of cyclosporine. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 543-544.	0.8	11
186	Efflux Transporter-Mediated Interactions With Atorvastatin—Interesting Findings With Multiple Substrates: Istradefylline, Verapamil, and Rifampicin. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 1492-1493.	1.0	3
187	Digoxin — a therapeutic agent and mechanistic probe: review of liquid chromatographic mass spectrometric methods and recent nuances in the clinical pharmacology attributes of digoxin. <i>Bioanalysis</i> , 2009, 1, 97-113.	0.6	11
188	Is There a Place for Drug Combination Strategies Using Clinical Pharmacology Attributes? — Review of Current Trends in Research. <i>Current Clinical Pharmacology</i> , 2009, 4, 220-228.	0.2	5
189	Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2008, 33, 247-252.	0.6	8
190	Allometric prediction of the human pharmacokinetic parameters for naveglitazar. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2008, 33, 187-190.	0.6	6
191	Dual drug interactions via P-glycoprotein (P-gp)/ cytochrome P450 (CYP3A4) interplay: recent case study of oral atorvastatin and verapamil. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 1135-1136.	0.8	12
192	Applicability of nonlinear calibration regression for quantitative determination of parent and metabolite(s) in bioequivalence assessment. <i>Biomedical Chromatography</i> , 2008, 22, 1315-1317.	0.8	7
193	A rapid and highly sensitive method for the determination of glimepiride in human plasma by liquid chromatography—electrospray ionization tandem mass spectrometry: application to a pre-clinical pharmacokinetic study. <i>Biomedical Chromatography</i> , 2008, 22, 58-63.	0.8	30
194	Changing need for bioanalysis during drug development. <i>Biomedical Chromatography</i> , 2008, 22, 235-243.	0.8	24
195	Development and validation of a sensitive LC-MS/MS method with electrospray ionization using multiple ions for quantitation of torcetrapib in hamster and dog plasma. <i>Biomedical Chromatography</i> , 2008, 22, 316-326.	0.8	11
196	Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of rhein in human plasma: application to a pharmacokinetic study. <i>Biomedical Chromatography</i> , 2008, 22, 616-624.	0.8	31
197	Interspecies scaling of a camptothecin analogue: Human predictions for intravenous topotecan using animal data. <i>Xenobiotica</i> , 2008, 38, 1377-1385.	0.5	9
198	Development and Validation of a Highly Sensitive and Robust LC-MS/MS with Electrospray Ionization Method for Quantification of Rosuvastatin in Small Volume Human Plasma Samples and its Application to a Clinical Study. <i>Arzneimittelforschung</i> , 2007, 57, 705-711.	0.5	14

#	ARTICLE	IF	CITATIONS
199	Concurrent determination of ezetimibe and its phase-I and II metabolites by HPLC with UV detection: Quantitative application to various in vitro metabolic stability studies and for qualitative estimation in bile. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 853, 88-96.	1.2	41
200	Development and validation of an enantioselective HPLC-UV method using Chiralpak AD-H to quantify (+)- and (âˆ’)-torcetrapib enantiomers in hamster plasma- application to a pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 857, 224-230.	1.2	8
201	Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2007, 32, 29-37.	0.6	13
202	Chiral bioanalysis of torcetrapib enantiomers in hamster plasma by normal-phase liquid chromatography and detection by atmospheric pressure chemical ionization tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 860, 227-234.	1.2	7
203	Bioavailability Enhancement of Poorly Water Soluble and Weakly Acidic New Chemical Entity with 2-Hydroxy Propyl-Î²-Cyclodextrin: Selection of Meglumine, a Polyhydroxy Base, as a Novel Ternary Component. <i>Pharmaceutical Development and Technology</i> , 2006, 11, 443-451.	1.1	15
204	Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. <i>Biomedical Chromatography</i> , 2006, 20, 125-132.	0.8	37
205	Analysis of five HMG-CoA reductase inhibitors- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. <i>Biomedical Chromatography</i> , 2006, 20, 282-293.	0.8	91
206	High-performance liquid chromatography method development and validation for simultaneous determination of five model compounds, antipyrine, metoprolol, ketoprofen, furosemide and phenol red, as a tool for the standardization of rat in situ intestinal permeability studies using timed wavelength detection. <i>Biomedical Chromatography</i> , 2006, 20, 349-357.	0.8	17
207	Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations. <i>Biomedical Chromatography</i> , 2006, 20, 383-414.	0.8	55
208	Determination of rosuvastatin in rat plasma by HPLC: validation and its application to pharmacokinetic studies. <i>Biomedical Chromatography</i> , 2006, 20, 881-887.	0.8	56
209	Simultaneous estimation of six anti-diabetic drugs- glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human plasma assay. <i>Biomedical Chromatography</i> , 2006, 20, 1043-1048.	0.8	78
210	Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. <i>Biomedical Chromatography</i> , 2006, 20, 1252-1259.	0.8	37
211	Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: Impact on oral bioavailability, absorption, and metabolic disposition in rats. <i>Xenobiotica</i> , 2006, 36, 838-856.	0.5	11
212	Validated HPLC analytical method with programmed wavelength UV detection for simultaneous determination of DRF-4367 and Phenol red in rat in situ intestinal perfusion study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2005, 38, 173-179.	1.4	15
213	Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC-MS/MS with electrospray ionization: Assay development, validation and application to a clinical study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2005, 39, 661-669.	1.4	73
214	METABOLISM, PHARMACOKINETICS, AND PROTEIN COVALENT BINDING OF RADIOLABELED MAXIPOST (BMS-204352) IN HUMANS. <i>Drug Metabolism and Disposition</i> , 2005, 33, 83-93.	1.7	50
215	Safety, Tolerability, and Pharmacokinetics of a Capsule Formulation of DRF-1042, a Novel Camptothecin Analog, in Refractory Cancer Patients in a Bridging Phase I Study. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 453-460.	1.0	16
216	Bioanalytical Aspects in Characterization and Quantification of Glucuronide Conjugates in Various Biological Matrices. <i>Current Pharmaceutical Analysis</i> , 2005, 1, 251-264.	0.3	15

#	ARTICLE	IF	CITATIONS
217	Role of Stereoselective Assays in Bioequivalence Studies of Racemic Drugs: Have We Reached a Consensus?. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 115-119.	1.0	9
218	Evaluation of experimental strategies for the development of chiral chromatographic methods based on diastereomer formation. <i>Biomedical Chromatography</i> , 2004, 18, 207-233.	0.8	67
219	Determination of lipoic acid in rat plasma by LC-MS/MS with electrospray ionization: Assay development, validation and application to a pharmacokinetic study. <i>Biomedical Chromatography</i> , 2004, 18, 681-686.	0.8	37
220	Clinical pharmacokinetic data of racemic drugs obtained by the indirect method following precolumn diastereomer formation: is the influence of racemization during chiral derivatization significant?. <i>Biomedical Chromatography</i> , 2004, 18, 343-349.	0.8	14
221	Simultaneous chiral analyses of multiple analytes: case studies, implications and method development considerations. <i>Biomedical Chromatography</i> , 2004, 18, 759-784.	0.8	28
222	Prediction of clinical pharmacokinetic parameters of linezolid using animal data by allometric scaling: applicability for the development of novel oxazolidinones. <i>Xenobiotica</i> , 2004, 34, 571-579.	0.5	13
223	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of an Orally Active Novel Camptothecin Analog, DRF-1042, in Refractory Cancer Patients in a Phase I Dose Escalation Study. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 723-736.	1.0	16
224	Quantitative determination of DRF-1042 in human plasma by HPLC: validation and application in clinical pharmacokinetics. <i>Biomedical Chromatography</i> , 2003, 17, 385-390.	0.8	9
225	Bioanalytical considerations for compounds containing free sulfhydryl groups. <i>Biomedical Chromatography</i> , 2003, 17, 285-291.	0.8	28
226	Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard. <i>Biomedical Chromatography</i> , 2003, 17, 417-420.	0.8	32
227	Resolution of enantiomers of ketoprofen by HPLC: a review. <i>Biomedical Chromatography</i> , 2003, 17, 423-434.	0.8	31
228	Open access™ generic method for continuous determination of major human CYP450 probe substrates/metabolites and its application in drug metabolism studies. <i>Xenobiotica</i> , 2003, 33, 1233-1245.	0.5	15
229	Lack of Effect of Sucralfate on the Absorption and Pharmacokinetics of Rosiglitazone. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 670-675.	1.0	14
230	Pharmacological and pharmacokinetic evaluation of celecoxib prodrugs in rats. <i>Biopharmaceutics and Drug Disposition</i> , 2002, 23, 273-282.	1.1	28
231	Quantitation of itraconazole in rat heparinized plasma by liquid chromatography-mass spectrometry. <i>Biomedical Applications</i> , 2001, 752, 9-16.	1.7	41
232	Enantiomeric drug development: Issues, considerations, and regulatory requirements. <i>Journal of Pharmaceutical Sciences</i> , 2001, 90, 1205-1215.	1.6	61
233	Sensitive liquid chromatographic-mass spectrometric assay for the simultaneous quantitation of nefazodone and its metabolites hydroxynefazodone m-chlorophenylpiperazine and triazole-dione in human plasma using single-ion monitoring. <i>Biomedical Applications</i> , 1998, 718, 77-85.	1.7	17
234	Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats. <i>Pharmaceutical Research</i> , 1997, 14, 911-916.	1.7	12

#	ARTICLE	IF	CITATIONS
235	Bioequivalence of Two Tablet Formulations of Nadolol Using Single and Multiple Dose Data: Assessment Using Stereospecific and Nonstereospecific Assays. <i>Journal of Pharmaceutical Sciences</i> , 1996, 85, 299-303.	1.6	19
236	Phase I and pharmacokinetic study of etoposide phosphate. <i>Anti-Cancer Drugs</i> , 1995, 6, 637-644.	0.7	16
237	Gas chromatographic determination of enantiomers as diastereomers following pre-column derivatization and applications to pharmacokinetic studies: A review. <i>Biomedical Chromatography</i> , 1995, 9, 1-9.	0.8	46
238	Simultaneous determination of nadolol enantiomers in human plasma by high-performance liquid chromatography using fluorescence-detection. <i>Biomedical Chromatography</i> , 1995, 9, 140-145.	0.8	18
239	A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 57, 499-507.	2.3	21
240	Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans. <i>Pharmaceutical Research</i> , 1993, 10, 14-21.	1.7	97
241	Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 52, 561-568.	2.3	116
242	Chiral separation by high performance liquid chromatography. I. Review on indirect separation of enantiomers as diastereomeric derivatives using ultraviolet, fluorescence and electrochemical detection. <i>Biomedical Chromatography</i> , 1992, 6, 163-167.	0.8	48
243	Stereoselective Urinary Pharmacokinetics of dl-threo-Methylphenidate and Its Major Metabolite in Humans. <i>Journal of Pharmaceutical Sciences</i> , 1992, 81, 747-749.	1.6	24
244	Extensive and enantioselective presystemic metabolism of dl-threo-methylphenidate in humans. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1991, 15, 213-220.	2.5	31
245	Evidence that Dogs Do Not Model Enantioselective Pharmacokinetics of dl-Methylphenidate in Humans. <i>Journal of Pharmaceutical Sciences</i> , 1991, 80, 707-708.	1.6	14
246	In vitro hydrolysis of RR,SS-threo-methylphenidate by blood esterases? differential and enantioselective interspecies variability. <i>Chirality</i> , 1991, 3, 99-103.	1.3	35
247	Enantioselective gas chromatographic assay with electron-capture detection for dl-ritalinic acid in plasma. <i>Biomedical Applications</i> , 1990, 530, 327-336.	1.7	25
248	Enantioselective Aspects of the Disposition of dl-threo-Methylphenidate after the Administration of a Sustained-Release Formulation to Children with Attention Deficit-Hyperactivity Disorder. <i>Journal of Pharmaceutical Sciences</i> , 1989, 78, 944-947.	1.6	49
249	Enantioselective gas chromatographic assays with electron-capture detection for methoxyphenamine and its three primary metabolites in human urine. <i>Biomedical Applications</i> , 1989, 487, 61-72.	1.7	13
250	Enantioselective gas chromatographic assay with electron-capture detection for dl-fenfluramine and dl-norfenfluramine in plasma. <i>Biomedical Applications</i> , 1988, 433, 105-117.	1.7	14
251	Stereoselective disposition of methylphenidate in children with attention-deficit disorder. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1987, 241, 300-6.	1.3	51